Skip to content
Peptigraph home

Tirzepatide and Retatrutide Together: What Is Known

Tirzepatide and Retatrutide taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GLP-1 / GIP dual agonistFDA approved (Mounjaro, Zepbound)TirzepatideFDA-approved dual GIP and GLP-1 receptor agonist; in a large trial, mean weight change at week 72 was -15.0% on 5-mg and -19.5% on 10-mg weekly doses.[15]GLP-1 & metabolicGLP-1 / GIP / glucagon triple agonistInvestigational · phase 3RetatrutideInvestigational triple GIP, GLP-1 and glucagon receptor agonist, not FDA-approved; a phase 3 TRIUMPH trial reported mean weight change of -25.0% at the 12-mg dose versus -3.9% with placebo.[1]GLP-1 & metabolic
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 108 results, 2 Oct 2026).

Retatrutide is not FDA approved, and we have no sourced data on combining it with Tirzepatide.
Each component

Side by side

Showing 8 of 12 fields where the two differ. Category, PCAC vote, Jul 2026, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.

FieldTirzepatideRetatrutide
ClassGLP-1 / GIP dual agonistGLP-1 / GIP / glucagon triple agonist
Also calledtirz, tirze, Mounjaro, Zepboundreta, GLP-3, LY3437943
FDA statusFDA approved (Mounjaro, Zepbound)Investigational · phase 3
WADANot on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.Prohibited by WADA (S0)Retatrutide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change.
Half-lifeapproximately 5 dayssubcutaneous · FDA label (Mounjaro)approximately 6 dayssubcutaneous · Lancet 2022, PMID 36354040
Human studies we summarised24 human (22 randomized or controlled) of 30 summarised11 human (11 randomized or controlled) of 16 summarised
Typical study doses
Vial sizes sold5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 24 mg, 30 mg, 36 mg, 40 mg, 50 mg, 60 mg
Related tools

Tirzepatide vs Retatrutide

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison

A dual agonist and a triple agonist

In tirzepatide's pivotal obesity trial, mean weight change at week 72 was -20.9% on 15 mg against -3.1% on placebo.[15]

Tirzepatide is a dual agonist of the GIP and GLP-1 receptors.[16]

Retatrutide adds glucagon-receptor activity, making it a triple agonist.[17]

In the retatrutide phase 3 obesity trial the top dose gave 25.0% weight loss versus 3.9% on placebo. Trial populations and durations differ from tirzepatide's, so the figures are not a direct comparison.[1]

No trial has combined them

A PubMed search on 2 Oct 2026 for retatrutide with tirzepatide matched 108 records.

Calculated from pubmed query (retatrutide[tiab] OR LY3437943[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab]); records matched 108; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date

Zepbound's label recommends against coadministration with any GLP-1 receptor agonist.[18]

Safety signals and legal status

In the tirzepatide obesity trial, adverse events caused discontinuation in 4.3%, 7.1% and 6.2% of the 5, 10 and 15 mg groups against 2.6% on placebo.[15]

FDA states that retatrutide cannot be used in compounding under federal law and is not a component of an FDA-approved drug.[19]

Zepbound (tirzepatide) is indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain the reduction long term in adults with obesity or with overweight and a weight-related comorbid condition.[18]

Common questions

Tirzepatide vs retatrutide: which is stronger?

Retatrutide's top dose reached 25.0% mean weight loss in its phase 3 obesity trial against 3.9% on placebo; no randomised trial compares it with tirzepatide directly.[1]

Can I take tirzepatide and retatrutide together?

The Zepbound label says coadministration with any GLP-1 receptor agonist is not recommended. This page cites no trial of the pairing.[18]

Is retatrutide FDA approved?

No. FDA's database search for retatrutide returned no approved products.[20]

Sources

  1. 1Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  2. 2FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  3. 3Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
  4. 4FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  5. 5Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  6. 6World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  7. 7These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  8. 8Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
  9. 9Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
  10. 10Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
  11. 11LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
  12. 12Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
  13. 13Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
  14. 14PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
  16. 16Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.The New England journal of medicine · 2021PMID 34170647Accessed 2 Oct 2026
  17. 17Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
  18. 18ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  19. 19Official web pageOfficial web page · web page
  20. 20Drugs@FDA (openFDA) search: active ingredient "retatrutide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.